EntryPoint Capital’s BioLife Solutions BLFS Stock Holding History

EntryPoint Capital’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,107	Closed	-$288K	–	799
2026 Q1	$288K	Buy	+15,107	New	+$334K	0.08%	481

Other funds holding BLFS

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EntryPoint Capital's BLFS Position: Q2 2026 in Review

EntryPoint Capital sold out of BioLife Solutions (BLFS) in Q2 2026, closing a stake of 15,107 shares — an estimated $288K sold.

EntryPoint Capital first reported a position in BLFS in Q1 2026 and held it in 1 quarter. The position peaked at $288K in Q1 2026. 217 funds tracked by Wall St. Rank hold BLFS as of Q2 2026.

EntryPoint Capital reported no remaining BioLife Solutions position as of Q2 2026 after selling out during the quarter.
EntryPoint Capital sold 15,107 BioLife Solutions shares in Q2 2026, an estimated $288K.
EntryPoint Capital first reported a position in BioLife Solutions in Q1 2026 and held it in 1 quarter.
EntryPoint Capital's BioLife Solutions position peaked at $288K in Q1 2026.
217 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.